Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer.

MLA

Appukkuttan, Sreevalsa, et al. “Budget Impact Analysis of Darolutamide for Treatment of Nonmetastatic Castration-Resistant Prostate Cancer.” Journal of Managed Care & Specialty Pharmacy, vol. 27, no. 2, Feb. 2021, pp. 166–74. EBSCOhost, https://doi.org/10.18553/jmcp.2020.20330.

APA

Appukkuttan, S., Farej, R., Miles, L., Purser, M., & Wen, L. (2021). Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer. Journal of Managed Care & Specialty Pharmacy, 27(2), 166–174. https://doi.org/10.18553/jmcp.2020.20330

Chicago

Appukkuttan, Sreevalsa, Ryan Farej, LaStella Miles, Molly Purser, and Lonnie Wen. 2021. “Budget Impact Analysis of Darolutamide for Treatment of Nonmetastatic Castration-Resistant Prostate Cancer.” Journal of Managed Care & Specialty Pharmacy 27 (2): 166–74. doi:10.18553/jmcp.2020.20330.